GeneDx Holdings Corp Ordinary Shares - Class A WGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
GeneDx Reports Third Quarter 2026 Financial Results
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Trading Information
- Previous Close Price
- $65.72
- Day Range
- $52.89–58.07
- 52-Week Range
- $32.21–170.87
- Bid/Ask
- $54.83 / $55.50
- Shares Outstanding
- 29.97M
- Market Cap
- $1.64B
- Volume/Avg
- 3M / 738,138
Key Statistics
- Price/Earnings (Normalized)
- 40.20
- Price/Sales
- 3.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,300
- Website
- https://www.genedx.com
Valuation
Metric | WGS |
|---|---|
Price/Earnings (Normalized) | 40.20 |
Price/Book Value | 6.71 |
Price/Sales | 3.51 |
Price/Cash Flow | — |
Price/Earnings
WGS
Financial Strength
Metric | WGS |
|---|---|
Quick Ratio | 3.67 |
Current Ratio | 4.16 |
Interest Coverage | −25.47 |
Quick Ratio
WGS
Profitability
Metric | WGS |
|---|---|
Return on Assets (Normalized) | −1.05% |
Return on Equity (Normalized) | −1.98% |
Return on Invested Capital (Normalized) | −0.27% |
Return on Assets
WGS
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|fq@>R?CN | LOCK|ZsV | $266B | |||
| Danaher Corp DHR | LOCK|fb?k<<Q | LOCK|&K | $166B | |||
| IDEXX Laboratories Inc IDXX | LOCK|H>pP^n^b | LOCK|<>N | $55B | |||
| Agilent Technologies Inc A | LOCK|%rZQFkX | LOCK|s^T | $50B | |||
| Waters Corp WAT | LOCK|^@&!BD | LOCK|p&# | $47B | |||
| IQVIA Holdings Inc IQV | LOCK|jcy>SF& | LOCK|XL%D | $45B | |||
| Mettler-Toledo International Inc MTD | LOCK|$fc>bLFp | LOCK|&&H% | $35B | |||
| Illumina Inc ILMN | LOCK|p<<!rj@ | LOCK|J$ztj | $32B | |||
| Labcorp Holdings Inc LH | LOCK|YK^B&V@S | LOCK|#&G< | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|RY$@P>K | LOCK|M$t^B | $29B |
United States